Biogen's Q1 results disappoint Wall Street Biogen today posted lower then expected quarterly profit and revenue as its key oral multiple sclerosis drug Tecfidera showed signs of slowing growth. Business • 24 Apr 15
Biogen's Q1 results disappoint Wall Street Biogen today posted lower then expected quarterly profit and revenue as its key oral multiple sclerosis drug Tecfidera showed signs of slowing growth. Business • 24 Apr 15
Biogen ups outlook as new MS drug tops forecasts Biogen Idec today reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations. Business • 23 Apr 14
Biogen ups outlook as new MS drug tops forecasts Biogen Idec today reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations. Business • 23 Apr 14
Biogen profits slip on tax accounting error Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error. Business • 28 Jan 13
Biogen profits slip on tax accounting error Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error. Business • 28 Jan 13
